Supplementary Information from A Potent <i>in Vivo</i> Antitumor Efficacy of Novel Recombinant Type I Interferon

Kang-Jian Zhang,Xiao-Fei Yin,Yuan-Qin Yang,Hui-Ling Li,Yan-Ni Xu,Lie-Yang Chen,Xi-Jun Liu,Su-Jing Yuan,Xian-Long Fang,Jing Xiao,Shuai Wu,Hai-Neng Xu,Liang Chu,Kanstantsin V. Katlinski,Yuliya V. Katlinskaya,Rong-Bing Guo,Guang-Wen Wei,Da-Cheng Wang,Xin-Yuan Liu,Serge Y. Fuchs

DOI: https://doi.org/10.1158/1078-0432.22466456

2023-01-01

Abstract:Supplementary methods, tables, figures and legends to figures Supplementary Figure 1. The structure of AB loops for sIFN-I and IFNα-2b and comparison on the sequences for sIFN-I and IFNα-21. Supplementary Figure 2. Quantification of phosphorylaiton of STAT1/3 in Figure 3C Supplementary Figure 3. Analysis of the cell surface IFNAR1 levels in the A549-IFNAR1-KO cell clones by FACS. Supplementary Figure 4. sIFN-I shows potent anti-solid tumor effect in immunocompromised mice models. Supplementary Figure 5. sIFN-I treatment decreases cell proliferation and induces senescence in vivo. Supplementary Figure 6. The antitumor effect of sIFN-I in immunocompetent tumor models. Supplementary Figure 7. FACS analysis of splenocytes from tumor-bearing mice treated with sIFN-I. Supplementary Table 1. Primer sequences used in this study. Supplementary Table 2. Primary antibodies used in this study. Supplementary Table 3. The pharmacokinetic index of human IFNα-2b or sIFN-I administered as in Figure 4B was analyzed by WinNonlin version 6.2 software.